PKR is not obligatory for high-fat diet-induced obesity and its associated metabolic and inflammatory complications

G I Lancaster1, H L Kammoun1, M J Kraakman1

  • 1Cellular and Molecular Metabolism Laboratory, BakerIDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.

Nature Communications
|February 4, 2016
PubMed

Insights

Protein kinase R (PKR) does not significantly impact high-fat diet-induced obesity or related metabolic issues. This study found PKR is not essential for sensing pro-inflammatory lipids, challenging its proposed role in metabolic disease.

Area of Science:

  • Biochemistry
  • Metabolism
  • Immunology

Background:

  • Protein kinase R (PKR) has been implicated in mediating adverse effects of high-fat diets (HFD).
  • Previous research shows considerable variability in metabolic outcomes following PKR deletion.
  • The precise role of PKR in diet-induced metabolic dysfunction remains unclear.

Purpose of the Study:

  • To re-evaluate the role of PKR in HFD-induced obesity and metabolic complications in vivo.
  • To investigate the putative lipid-sensing role of PKR in vitro.
  • To clarify PKR's involvement in inflammation triggered by saturated fatty acids.

Main Methods:

  • Utilized PKR knockout (PKR KO) and wild-type (WT) mouse models fed a high-fat diet.
  • Assessed obesity, hepatic steatosis, glucose metabolism, and adipose tissue inflammation.
  • Examined inflammatory responses in WT and PKR KO macrophages treated with palmitate in vitro.

Main Results:

  • PKR deletion did not alter HFD-induced obesity, hepatic steatosis, or glucose metabolism.
  • Adipose tissue inflammation was only modestly affected by PKR deletion.
  • Palmitate treatment induced similar inflammation levels in WT and PKR KO macrophages, indicating PKR is dispensable for lipid-sensing.

Conclusions:

  • PKR does not play a critical role in the development of obesity or associated metabolic complications driven by HFD.
  • PKR is not required for macrophages to sense and respond to pro-inflammatory saturated fatty acids.
  • These findings challenge the established role of PKR in metabolic disease pathogenesis and lipid-induced inflammation.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.2K